Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2016 1
2018 2
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Results by year

Filters applied: . Clear all
Page 1
Impact of steatosis and inflammation definitions on the performance of NASH tests.
Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, Pais R, Mathurin P, Ratziu V; FLIP consortium, the FibroFrance-CPAM group; FibroFrance-Obese group. Poynard T, et al. Eur J Gastroenterol Hepatol. 2018 Apr;30(4):384-391. doi: 10.1097/MEG.0000000000001033. Eur J Gastroenterol Hepatol. 2018. PMID: 29280921 Free PMC article.
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, Trauner M, Romero Gomez M, Oliveira C, Day C, Dufour JF, Bellentani S, Ngo Y, Traussnig S, Perazzo H, Deckmyn O, Bedossa P, Ratziu V, Poynard T; FLIP Consortium and the FibroFrance Group. Munteanu M, et al. Aliment Pharmacol Ther. 2016 Oct;44(8):877-89. doi: 10.1111/apt.13770. Epub 2016 Aug 23. Aliment Pharmacol Ther. 2016. PMID: 27549244 Free PMC article.
Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia.
Perazzo H, Munteanu M, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, Jacqueminet S, Giral P, Monneret D, Imbert-Bismut F, Ratziu V, Hartemann-Huertier A, Housset C, Poynard T; FLIP Consortium. Perazzo H, et al. Aliment Pharmacol Ther. 2014 Nov;40(9):1081-93. doi: 10.1111/apt.12946. Epub 2014 Sep 3. Aliment Pharmacol Ther. 2014. PMID: 25186086 Free article.
The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis.
Poynard T, Peta V, Munteanu M, Charlotte F, Ngo Y, Ngo A, Perazzo H, Deckmyn O, Pais R, Mathurin P, Myers R, Loomba R, Ratziu V; FLIP consortium, the FibroFrance-CPAM group, the FibroFrance-Obese group, and the Selonsertib group. Poynard T, et al. Eur J Gastroenterol Hepatol. 2019 Mar;31(3):393-402. doi: 10.1097/MEG.0000000000001304. Eur J Gastroenterol Hepatol. 2019. PMID: 30516570 Free PMC article.
Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference.
Poynard T, Munteanu M, Charlotte F, Perazzo H, Ngo Y, Deckmyn O, Pais R, Merrouche W, de Ledinghen V, Mathurin P, Ratziu V; FLIP Consortium, the FibroFrance-CPAM Group, the FibroFrance-Obese Group. Poynard T, et al. Eur J Gastroenterol Hepatol. 2018 May;30(5):569-577. doi: 10.1097/MEG.0000000000001064. Eur J Gastroenterol Hepatol. 2018. PMID: 29406435
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V; FLIP consortium. Poynard T, et al. PLoS One. 2012;7(3):e30325. doi: 10.1371/journal.pone.0030325. Epub 2012 Mar 14. PLoS One. 2012. PMID: 22431959 Free PMC article.
Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes.
Poynard T, Peta V, Deckmyn O, Pais R, Ngo Y, Charlotte F, Ngo A, Munteanu M, Imbert-Bismut F, Monneret D, Housset C, Thabut D, Valla D, Boitard C, Castera L, Ratziu V; FLIP consortium, the FibroFrance Group, the EPIC-3 program and the QUID-NASH group. Poynard T, et al. Eur J Gastroenterol Hepatol. 2020 Aug;32(8):998-1007. doi: 10.1097/MEG.0000000000001606. Eur J Gastroenterol Hepatol. 2020. PMID: 31789950 Free PMC article.